Galectin Therapeutics (GALT) News
NASDAQ: GALTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
2.69-0.12 (-4.27%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GALT news summary
We found 2 recent headlines mentioning Galectin Therapeutics (GALT): 2 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, GALT is down 4.27% at $2.69. The most recent story, "Galectin Therapeutics Inc. Reports September 30, 2026 Financial Results and $105.8 million Debt Conversion", was published by Nasdaq on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Galectin Therapeutics headlines
- Galectin Therapeutics Inc. Reports September 30, 2026 Financial Results and $105.8 million Debt ConversionGalectin Therapeutics Inc. reported financial results and provided a business update for the three months ended September 30, 2026. During the third quarter, the company submitted its registrational…Nasdaq
- Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business UpdateNORCROSS, Ga., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and…GlobeNewswire